This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a McGill University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $444,274
Exergaming registry-based trial promoting physical activity in children and adolescents with spinal muscular atrophy
CIHR · 2022 · Principal investigator
- $293,643
The Safety and Efficacy of Adalimumab for Pain Reduction in Individuals with Mucopolysaccharidoses: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial
CIHR · 2022 · Principal investigator
- $1,777,095
Exergaming registry-based trial promoting physical activity in children and adolescents with spinal muscular atrophy
CIHR · 2022 · Principal investigator
Exergaming registry-based trial promoting physical activity in children and adolescents with spinal muscular atrophy
Principal investigators: Oskoui, Maryam; Smith, Maureen M; Evans, Alan C; Iturria Medina, Yasser; Levac, Danielle E; Potter, Elizabeth K
Keywords: Exergaming; Pragmatic Randomized Controlled Trial; Rare Disease; Registry-Based Trial; Rehabilitation; Spinal Muscular Atrophy; Wearable Technology
The Safety and Efficacy of Adalimumab for Pain Reduction in Individuals with Mucopolysaccharidoses: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial
Principal investigators: Mitchell, John J; Smith, Maureen M; Inbar-Feigenberg, Michal; Jain, Shailly; Polgreen, Lynda; Potter, Elizabeth K
Keywords: Growth; Mucopolysaccharidoses; Pain; Quality Of Life; Rare Disease; Tnf-Alpha
Exergaming registry-based trial promoting physical activity in children and adolescents with spinal muscular atrophy
Principal investigators: Oskoui, Maryam; Smith, Maureen M; Evans, Alan C; Iturria Medina, Yasser; Levac, Danielle E; Potter, Elizabeth K
Keywords: Exergaming; Pragmatic Randomized Controlled Trial; Rare Disease; Registry-Based Trial; Rehabilitation; Spinal Muscular Atrophy; Wearable Technology
The Safety and Efficacy of Adalimumab for Pain Reduction in Individuals with Mucopolysaccharidoses: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial
Principal investigators: Mitchell, John J; Smith, Maureen M; Inbar-Feigenberg, Michal; Jain, Shailly; Polgreen, Lynda; Potter, Elizabeth K
Keywords: Growth; Mucopolysaccharidoses; Pain; Quality Of Life; Rare Disease; Tnf-Alpha
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.